Bayesian Analysis: A Practical Approach to Interpret Clinical Trials and Create Clinical Practice Guidelines

Circulation: Cardiovascular Quality and Outcomes

Volumn 10, Issue 8, 2017, Pages

  Bittl, John A ^a   He, Yulei ^b  

^a Munroe Regional Med Center   (United States)

^b NATIONAL CENTER FOR HEALTH STATISTICS   (United States)

Author keywords

Bayes theorem; diabetes mellitus; probability; statistical distributions; statistics

Indexed keywords

ANTITHROMBOCYTIC AGENT;

ALL CAUSE MORTALITY; ARTICLE; BAYES THEOREM; BYPASS SURGERY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; DIABETIC PATIENT; DRUG ELUTING STENT; DUAL ANTIPLATELET THERAPY; EVIDENCE BASED PRACTICE; FOLLOW UP; HEART INFARCTION; HUMAN; META ANALYSIS (TOPIC); MORTALITY RATE; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVASCULARIZATION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TREATMENT DURATION; CORONARY ARTERY BYPASS GRAFT; DEVICES; DIABETES MELLITUS; EVIDENCE BASED MEDICINE; META ANALYSIS; METHODOLOGY; OBSERVATIONAL STUDY; ODDS RATIO; RISK FACTOR; STANDARDS; STATISTICAL ANALYSIS; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

BAYES THEOREM; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; DATA INTERPRETATION, STATISTICAL; DIABETES MELLITUS; DRUG-ELUTING STENTS; EVIDENCE-BASED MEDICINE; HUMANS; MODELS, STATISTICAL; OBSERVATIONAL STUDIES AS TOPIC; ODDS RATIO; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RISK FACTORS; ST ELEVATION MYOCARDIAL INFARCTION; TREATMENT OUTCOME;

EID: 85028722721     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.117.003563     Document Type: Article

References (56)

1. O'Hagan A, Luce BR. A Primer on Bayesian Statistics in Health Economics and Outcomes Research. Bethesda, MD: MEDTAP International; 2003.
2. Bertsekas DP, Tsitsiklas JN. Introduction to Probability. Belmont, MA: Athena Scientific; 2008.
3. Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian Approaches to Clinical Trials and Health Care Evaluations. Chichester, England: Wiley; 2004.
4. Goodman SN. Toward evidence-based medical statistics. 1: the P value fallacy. Ann Intern Med. 1999;130:995-1004.
5. Carlin JB, Louis TA. Bayesian Methods for Data Analysis. Boca Raton, FL: Chapman & Hall/CRC; 2009.
6. Diamond GA, Kaul S. Prior convictions: Bayesian approaches to the analysis and interpretation of clinical megatrials. J Am Coll Cardiol. 2004;43:1929-1939. doi: 10.1016/j.jacc.2004.01.035.
7. Greenland S, Senn SJ, Rothman KJ, Carlin JB, Poole C, Goodman SN, Altman DG. Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations. Eur J Epidemiol. 2016;31:337-350. doi: 10.1007/s10654-016-0149-3.
8. Gregory PC. A Bayesian Kepler periodogram detects a second planet in HD208487. Month Notic Royal Astronom Soc. 2007;374:1321-1333.
9. Fernando RL, Garrick D. Bayesian methods applied to GWAS. Methods Mol Biol. 2013;1019:237-274. doi: 10.1007/978-1-62703-447-0-10.
10. Jacobs AK, Kushner FG, Ettinger SM, Guyton RA, Anderson JL, Ohman EM, Albert NM, Antman EM, Arnett DK, Bertolet M, Bhatt DL, Brindis RG, Creager MA, DeMets DL, Dickersin K, Fonarow GC, Gibbons RJ, Halperin JL, Hochman JS, Koster MA, Normand SL, Ortiz E, Peterson ED, Roach WHJ, Sacco RL, Smith SCJ, Stevenson WG, Tomaselli GF, Yancy CW, Zoghbi WA, Harold JG, He Y, Mangu P, Qaseem A, Sayre MR, Somerfield MR. ACCF/AHA clinical practice guideline methodology summit report: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61:213-265.
11. Bittl JA, He Y, Jacobs AK, Yancy CW, Normand SL; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Bayesian methods affirm the use of percutaneous coronary intervention to improve survival in patients with unprotected left main coronary artery disease. Circulation. 2013;127:2177-2185. doi: 10.1161/CIRCULATIONAHA.112.000646.
12. Welton N, Sutton AJ, Cooper NJ, Abrams KR, Ades AE. Evidence Synthesis for Decision Making in Healthcare. Chichester, West Sussex, United Kingdom: Wiley; 2012.
13. Kruschke JK. Doing Bayesian Data Analysis: A Tutorial With R and BUGS. Oxford, England: Elsevier; 2011.
14. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2013.
15. Schwarzer G. Package 'Meta' (version 3.8-0). Comprehensive R Archive Network (CRAN). Freiburg, Germany: 2012.
16. Thomas A, O'Hara B, Ligges U, Sturtz S. Making BUGS open. R News. 2006;6:12-17.
17. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011;124:e574-e651. doi: 10.1161/CIR.0b013e31823ba622.
18. Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, Yang M, Cohen DJ, Rosenberg Y, Solomon SD, Desai AS, Gersh BJ, Magnuson EA, Lansky A, Boineau R, Weinberger J, Ramanathan K, Sousa JE, Rankin J, Bhargava B, Buse J, Hueb W, Smith CR, Muratov V, Bansilal S, King S III, Bertrand M, Fuster V; FREEDOM Trial Investigators. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med. 2012;367:2375-2384. doi: 10.1056/NEJMoa1211585.
19. Verma S, Farkouh ME, Yanagawa B, Fitchett DH, Ahsan MR, Ruel M, Sud S, Gupta M, Singh S, Gupta N, Cheema AN, Leiter LA, Fedak PW, Teoh H, Latter DA, Fuster V, Friedrich JO. Comparison of coronary artery bypass surgery and percutaneous coronary intervention in patients with diabetes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2013;1:317-328. doi: 10.1016/S2213-8587(13)70089-5.
20. Bittl JA. Percutaneous coronary interventions in the diabetic patient: where do we stand Circ Cardiovasc Interv. 2015;8:e001944. doi: 10.1161/CIRCINTERVENTIONS.114.001944.
21. Lang CD, He Y, Bittl JA. Bayesian inference supports the use of bypass surgery over percutaneous coronary intervention to reduce mortality in diabetic patients with multivessel coronary disease. Int J Stat Med Res. 2015;4:26-34.
22. The BARI Investigators. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI). Circulation. 1997;96:1761-1769.
23. Abizaid A, Costa MA, Centemero M, Abizaid AS, Legrand VM, Limet RV, Schuler G, Mohr FW, Lindeboom W, Sousa AG, Sousa JE, van Hout B, Hugenholtz PG, Unger F, Serruys PW; Arterial Revascularization Therapy Study Group. Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: insights from the Arterial Revascularization Therapy Study (ARTS) trial. Circulation. 2001;104:533-538.
24. Rodriguez AE, Baldi J, Fernández Pereira C, Navia J, Rodriguez Alemparte M, Delacasa A, Vigo F, Vogel D, O'Neill W, Palacios IF; ERACI II Investigators. Five-year follow-up of the Argentine randomized trial of coronary angioplasty with stenting versus coronary bypass surgery in patients with multiple vessel disease (ERACI II). J Am Coll Cardiol. 2005;46:582-588. doi: 10.1016/j.jacc.2004.12.081.
25. Hueb W, Gersh BJ, Costa F, Lopes N, Soares PR, Dutra P, Jatene F, Pereira AC, Góis AF, Oliveira SA, Ramires JA. Impact of diabetes on five-year outcomes of patients with multivessel coronary artery disease. Ann Thorac Surg. 2007;83:93-99. doi: 10.1016/j.athoracsur.2006.08.050.
26. The SoS Investigators. Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): a randomised controlled trial. Lancet. 2002;360:965-970.
27. Kapur A, Hall RJ, Malik IS, Qureshi AC, Butts J, de Belder M, Baumbach A, Angelini G, de Belder A, Oldroyd KG, Flather M, Roughton M, Nihoyannopoulos P, Bagger JP, Morgan K, Beatt KJ. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. J Am Coll Cardiol. 2010;55:432-440. doi: 10.1016/j.jacc.2009.10.014.
28. Kappetein AP, Head SJ, Morice MC, Banning AP, Serruys PW, Mohr FW, Dawkins KD, Mack MJ; SYNTAX Investigators. Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial. Eur J Cardiothorac Surg. 2013;43:1006-1013. doi: 10.1093/ejcts/ezt017.
29. Kamalesh M, Sharp TG, Tang XC, Shunk K, Ward HB, Walsh J, King S III, Colling C, Moritz T, Stroupe K, Reda D; VA CARDS Investigators. Percutaneous coronary intervention versus coronary bypass surgery in United States veterans with diabetes. J Am Coll Cardiol. 2013;61:808-816. doi: 10.1016/j.jacc.2012.11.044.
30. Bittl JA, Tamis-Holland JE, Lang CD, He Y. Outcomes after multivessel or culprit-Vessel intervention for ST-elevation myocardial infarction in patients with multivessel coronary disease: a Bayesian cross-design meta-analysis. Catheter Cardiovasc Interv. 2015;86(suppl 1):S15-S22. doi: 10.1002/ccd.26025.
31. Goodman SN. Toward evidence-based medical statistics. 2: The Bayes factor. Ann Intern Med. 1999;130:1005-1013.
32. Armitage P, Berry G, Matthews JNS. Bayesian methods. Statistical Methods in Clinical Research. Malden, MA: Blackwell Science; 2002:165-186.
33. Fihn SD, Blankenship JC, Alexander KP, Bittl JA, Byrne JG, Fletcher BJ, Fonarow GC, Lange RA, Levine GN, Maddox TM, Naidu SS, Ohman EM, Smith PK. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2014;130:1749-1767. doi: 10.1161/CIR.0000000000000095.
34. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR Jr, Krucoff MW, Hermiller J, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow TK, Ver Lee P, Rinaldi MJ, Massaro JM; DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371:2155-2166. doi: 10.1056/NEJMoa1409312.
35. Palmerini T, Benedetto U, Bacchi-Reggiani L, Della Riva D, Biondi-Zoccai G, Feres F, Abizaid A, Hong MK, Kim BK, Jang Y, Kim HS, Park KW, Genereux P, Bhatt DL, Orlandi C, De Servi S, Petrou M, Rapezzi C, Stone GW. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. Lancet. 2015;385:2371-2382. doi: 10.1016/S0140-6736(15)60263-X.
36. Bittl JA, Baber U, Bradley SM, Wijeysundera DN. Duration of dual antiplatelet therapy: a systematic review for the 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016;68:1116-1139. doi: 10.1016/j.jacc.2016.03.512.
37. Food and Drug Administration. Plavix (clopidogrel): long-term treatment does not change risk of death. Drug Safety Communication. 2015; 1-6.
38. Kim BK, Hong MK, Shin DH, Nam CM, Kim JS, Ko YG, Choi D, Kang TS, Park BE, Kang WC, Lee SH, Yoon JH, Hong BK, Kwon HM, Jang Y; RESET Investigators. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol. 2012;60:1340-1348. doi: 10.1016/j.jacc.2012.06.043.
39. Feres F, Costa RA, Abizaid A, Leon MB, Marin-Neto JA, Botelho RV, King SB III, Negoita M, Liu M, de Paula JE, Mangione JA, Meireles GX, Castello HJ Jr, Nicolela EL Jr, Perin MA, Devito FS, Labrunie A, Salvadori D Jr, Gusmao M, Staico R, Costa JR Jr, de Castro JP, Abizaid AS, Bhatt DL; OPTIMIZE Trial Investigators. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA. 2013;310:2510-2522. doi: 10.1001/jama.2013.282183.
40. Gwon HC, Hahn JY, Park KW, Song YB, Chae IH, Lim DS, Han KR, Choi JH, Choi SH, Kang HJ, Koo BK, Ahn T, Yoon JH, Jeong MH, Hong TJ, Chung WY, Choi YJ, Hur SH, Kwon HM, Jeon DW, Kim BO, Park SH, Lee NH, Jeon HK, Jang Y, Kim HS. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation. 2012;125:505-513. doi: 10.1161/CIRCULATIONAHA.111.059022.
41. Colombo A, Chieffo A, Frasheri A, Garbo R, Masotti-Centol M, Salvatella N, Oteo Dominguez JF, Steffanon L, Tarantini G, Presbitero P, Menozzi A, Pucci E, Mauri J, Cesana BM, Giustino G, Sardella G. Second-generation drug-eluting stent implantation followed by 6-versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. J Am Coll Cardiol. 2014;64:2086-2097. doi: 10.1016/j.jacc.2014.09.008.
42. Schulz-Schüpke S, Byrne RA, Ten Berg JM, Neumann FJ, Han Y, Adriaenssens T, Tölg R, Seyfarth M, Maeng M, Zrenner B, Jacobshagen C, Mudra H, von Hodenberg E, Wöhrle J, Angiolillo DJ, von Merzljak B, Rifatov N, Kufner S, Morath T, Feuchtenberger A, Ibrahim T, Janssen PW, Valina C, Li Y, Desmet W, Abdel-Wahab M, Tiroch K, Hengstenberg C, Bernlochner I, Fischer M, Schunkert H, Laugwitz KL, Schömig A, Mehilli J, Kastrati A; Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) Trial Investigators. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. Eur Heart J. 2015;36:1252-1263. doi: 10.1093/eurheartj/ehu523.
43. Han Y, Xu B, Xu K, Guan C, Jing Q, Zheng Q, Li X, Zhao X, Wang H, Zhao X, Li X, Yu P, Zang H, Wang Z, Cao X, Zhang J, Pang W, Li J, Yang Y, Dangas GD. Six versus 12 months of dual antiplatelet therapy after implantation of biodegradable polymer sirolimus-eluting stent: randomized substudy of the I-LOVE-IT 2 trial. Circ Cardiovasc Interv. 2016;9:e003145. doi: 10.1161/CIRCINTERVENTIONS.115.003145.
44. Hong SJ, Shin DH, Kim JS, Kim BK, Ko YG, Choi D, Her AY, Kim YH, Jang Y, Hong MK; IVUS-XPL Investigators. 6-Month versus 12-month dual-antiplatelet therapy following long everolimus-eluting stent implantation: the IVUS-XPL randomized clinical trial. JACC Cardiovasc Interv. 2016;9:1438-1446. doi: 10.1016/j.jcin.2016.04.036.
45. Collet JP, Silvain J, Barthélémy O, Rangé G, Cayla G, Van Belle E, Cuisset T, Elhadad S, Schiele F, Lhoest N, Ohlmann P, Carrié D, Rousseau H, Aubry P, Monségu J, Sabouret P, O'Connor SA, Abtan J, Kerneis M, Saint-Etienne C, Beygui F, Vicaut E, Montalescot G; ARCTIC investigators. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial. Lancet. 2014;384:1577-1585. doi: 10.1016/S0140-6736(14)60612-7.
46. Lee CW, Ahn JM, Park DW, Kang SJ, Lee SW, Kim YH, Park SW, Han S, Lee SG, Seong IW, Rha SW, Jeong MH, Lim DS, Yoon JH, Hur SH, Choi YS, Yang JY, Lee NH, Kim HS, Lee BK, Kim KS, Lee SU, Chae JK, Cheong SS, Suh IW, Park HS, Nah DY, Jeon DS, Seung KB, Lee K, Jang JS, Park SJ. Optimal duration of dual antiplatelet therapy after drugeluting stent implantation: a randomized, controlled trial. Circulation. 2014;129:304-312. doi: 10.1161/CIRCULATIONAHA.113.003303.
47. Helft G, Steg PG, Le Feuvre C, Georges JL, Carrie D, Dreyfus X, Furber A, Leclercq F, Eltchaninoff H, Falquier JF, Henry P, Cattan S, Sebagh L, Michel PL, Tuambilangana A, Hammoudi N, Boccara F, Cayla G, Douard H, Diallo A, Berman E, Komajda M, Metzger JP, Vicaut E; OPTImal DUAL Antiplatelet Therapy Trial Investigators. Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial. Eur Heart J. 2016;37:365-374. doi: 10.1093/eurheartj/ehv481.
48. Valgimigli M, Campo G, Monti M, Vranckx P, Percoco G, Tumscitz C, Castriota F, Colombo F, Tebaldi M, Fuca G, Kubbajeh M, Cangiano E, Minarelli M, Scalone A, Cavazza C, Frangione A, Borghesi M, Marchesini J, Parrinello G, Ferrari R; Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) Investigators. Short-versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation. 2012;125:2015-2026. doi: 10.1161/CIRCULATIONAHA.111.071589.
49. Gilard M, Barragan P, Noryani AA, Noor HA, Majwal T, Hovasse T, Castellant P, Schneeberger M, Maillard L, Bressolette E, Wojcik J, Delarche N, Blanchard D, Jouve B, Ormezzano O, Paganelli F, Levy G, Sainsous J, Carrie D, Furber A, Berland J, Darremont O, Le Breton H, Lyuycx-Bore A, Gommeaux A, Cassat C, Kermarrec A, Cazaux P, Druelles P, Dauphin R, Armengaud J, Dupouy P, Champagnac D, Ohlmann P, Endresen K, Benamer H, Kiss RG, Ungi I, Boschat J, Morice MC. 6-versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial. J Am Coll Cardiol. 2015;65:777-786. doi: 10.1016/j.jacc.2014.11.008.
50. Nakamura M, Iijima R, Ako J, Shinke T, Okada H, Ito Y, Ando K, Anzai H, Tanaka H, Ueda Y, Takiuchi S, Nishida Y, Ohira H, Kawaguchi K, Kadotani M, Niinuma H, Omiya K, Morita T, Zen K, Yasaka Y, Inoue K, Ishiwata S, Ochiai M, Hamasaki T, Yokoi H; NIPPON Investigators. Dual antiplatelet therapy for 6 versus 18 months after biodegradable polymer drug-eluting stent implantation. JACC Cardiovasc Interv. 2017;10:1189-1198. doi: 10.1016/j.jcin.2017.04.019.
51. Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, Granger CB, Lange RA, Mack MJ, Mauri L, Mehran R, Mukherjee D, Newby LK, O'Gara PT, Sabatine MS, Smith PK, Smith SC Jr. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016;68:1082-1115. doi: 10.1016/j.jacc.2016.03.513.
52. Cates CJ. Simpson's paradox and calculation of number needed to treat from meta-analysis. BMC Med Res Methodol. 2002;2:1.
53. Bates ER, Tamis-Holland JE, Bittl JA, O'Gara PT, Levine GN. PCI strategies in patients with ST-segment elevation myocardial infarction and multivessel coronary artery disease. J Am Coll Cardiol. 2016;68:1066-1081. doi: 10.1016/j.jacc.2016.05.086.
54. He Y, Bittl JA, Wouhib A, Normand S-LT. Case study in cardiovascular medicine: unprotected left main coronary artery disease. In: Biondi-Zoccai G, ed. Network Meta-Analysis: Evidence Synthesis With Mixed Treatment Comparison. New York: Nova Science Publishers, Inc; 2014:285-386.
55. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Ting HH, O'Gara PT, Kushner FG, Ascheim DD, Brindis RG, Casey DE Jr, Chung MK, de Lemos JA, Diercks DB, Fang JC, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX. 2015 ACC/AHA/SCAI focused update on primary percutaneous coronary intervention for patients with STelevation myocardial infarction: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. J Am Coll Cardiol. 2016;67:1235-1250. doi: 10.1016/j.jacc.2015.10.005.
56. Olson WH, Crivera C, Ma YW, Panish J, Mao L, Lynch SM. Bayesian data analysis in observational comparative effectiveness research: rationale and examples. J Comp Eff Res. 2013;2:563-571. doi: 10.2217/cer.13.73.